More than half of patients with neuroblastoma (NB) present with high-risk (HR) disease and still have long-term outcomes that remain inferior to those of many other childhood malignancies 1. Treatment ...

Eligible patients were 2–30 years of age, with biopsy-confirmed H3K27M-mutated DIPG or sDMG, who had completed standard frontline radiotherapy at least 4 weeks before enrolment, were not receiving ...

Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo. Background: Neuroblastoma is the most common extracranial solid tumor of childhood.

Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study Patients with relapsed high-risk neuroblastoma (rHR ...

Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is ...

From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in ...

Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from the ...